Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 113OTHER 92NETWORK 7OTHER_GOV 2NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1Disease Progression 1

Interventions

Dexamethasone 4Cyclophosphamide 4pomalidomide 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2fludarabine 2carfilzomib 2Etoposide 2Cytarabine 2Bortezomib 2fosaprepitant 1fludarabine phosphate 1daratumumab 1Zoledronic Acid 1Vaccination 1Tropisetron 1Thiotepa 1Renal Replacement Therapy 1Prednisone 1Pneumococcal Vaccines 1Olanzapine 1Melphalan 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Cyclosporine 1Azacitidine 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × pomalidomide × Plasma cell × Clear all
NCT04234022 2026-04-09

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

The Royal Wolverhampton Hospitals NHS Trust

Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

NCT03601624 2018-11-14

MM-POM-2018

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Phase 2 Unknown
18 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡